{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:05:03Z","timestamp":1793649903444,"version":"4.5.1"},"reference-count":37,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["18-1030"],"award-info":[{"award-number":["18-1030"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008358","name":"Hersenstichting","doi-asserted-by":"publisher","award":["HA2015.01.05"],"award-info":[{"award-number":["HA2015.01.05"]}],"id":[{"id":"10.13039\/501100008358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009248","name":"Innovatiefonds Zorgverzekeraars","doi-asserted-by":"publisher","award":["B 18-313\/ File 3.789"],"award-info":[{"award-number":["B 18-313\/ File 3.789"]}],"id":[{"id":"10.13039\/501100009248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,10,5]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The NEXT-MS trial is an investigator-initiated prospective phase IV non-randomised study. Adults with a diagnosis of relapsing-remitting MS who received \u22656 natalizumab infusions were included in three groups: personalised EID with a target drug trough concentration of 10\u2009\u00b5g\/mL (EID10), an exploratory group of personalised EID with a target of 5\u2009\u00b5g\/mL (EID5) and standard interval dosing (SID) of 4 weeks. The primary outcome is radiological disease activity (new\/newly enlarged T2 lesions) comparing the EID10 group to a historical cohort of SID (HSID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results of the first phase of the NEXT-MS trial are reported here (n=376) as the study will continue with an amended protocol. In the EID10 group (n=251), incidence rate of radiological activity was 10.0 per 1000 person-years, which was non-inferior to the HSID cohort (24.7 per 1000 person-years (n=87), incidence rate difference 14.7, 90%\u2009CI \u22124.5 to 34.0). Incidence rate of radiological activity was 10.0 per 1000 person-years in the EID5 group (n=65), and 47.0 per 1000 person-years in the SID group (n=60). Serum neurofilament light levels did not increase over time within the EID groups. There were no cases of progressive multifocal leukoencephalopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MS disease activity is adequately controlled with personalised natalizumab EID. Interval extension to a drug trough concentration of 5\u2009\u00b5g\/mL is likely a safe target to extend natalizumab treatment intervals &gt;6 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04225312\">NCT04225312<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2023-332119","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:20:29Z","timestamp":1699968029000},"page":"392-400","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)"],"prefix":"10.1136","volume":"95","clinical-trial-number":[{"clinical-trial-number":"nct04225312","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03689972","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04260711","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05296161","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7196-9826","authenticated-orcid":false,"given":"Alyssa A","family":"Toorop","sequence":"first","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb YGJ","family":"van Lierop","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza MY","family":"Gelissen","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoitsma","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Alrijne Hospital, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther MPE","family":"Zeinstra","sequence":"additional","affiliation":[{"name":"Department of Neurology, Isala, Meppel, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk C","family":"van Rooij","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar EP","family":"van Munster","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amphia Hospital, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Flevoziekenhuis, Almere, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop P","family":"Mostert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs HA","family":"Wokke","sequence":"additional","affiliation":[{"name":"Department of Neurology, ErasMS, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke F","family":"Kalkers","sequence":"additional","affiliation":[{"name":"Department of Neurology, OLVG Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin LJ","family":"Hoogervorst","sequence":"additional","affiliation":[{"name":"Department of Neurology, St Antonius Hospital, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen JJ","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-5225","authenticated-orcid":false,"given":"Christiaan M","family":"Roosendaal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Slingeland Hospital, Doetinchem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolijn J","family":"Kragt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Reinier de Graaf Hospital, Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Eurelings","sequence":"additional","affiliation":[{"name":"Department of Neurology, Spaarne Gasthuis, Haarlem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"van Genugten","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ziekenhuisgroep Twente, Almelo, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ommelander Hospital Groningen, Scheemda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LGF","family":"Sinnige","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Kloosterziel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wilhelmina Hospital Assen, Assen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo PJ","family":"Arnoldus","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elisabeth TweeSteden Hospital, Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert W","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H","family":"Bouvy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Diakonessenhuis Hospital, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark HJ","family":"Wessels","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Boonkamp","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-5864","authenticated-orcid":false,"given":"Eva MM","family":"Strijbis","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W","family":"van Oosten","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A","family":"De Jong","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I","family":"Lissenberg-Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"},{"name":"Queen Square MS Centre, Department of Neuroinflammation, Faculty of Brain Sciences, University College London Hospitals and National Institute for Health Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Moraal","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"Diagnostic Services and Immunopathology, Sanquin Research, Amsterdam, The Netherlands"},{"name":"Department of Immunopathology, Landsteiner Laboratory, University of Amsterdam, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard MJ","family":"Uitdehaag","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-5381","authenticated-orcid":false,"given":"Zo\u00e9 LE","family":"van Kempen","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2026081401350938000_95.5.392.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026081401350938000_95.5.392.2","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000672","article-title":"Pharmacodynamics of natalizumab extended interval dosing in MS","volume":"7","author":"Zhovtis Ryerson","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350938000_95.5.392.3","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"2026081401350938000_95.5.392.4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03914-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350938000_95.5.392.5","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"2026081401350938000_95.5.392.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.01.001"},{"key":"2026081401350938000_95.5.392.7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026081401350938000_95.5.392.8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of Natalizumab-treated MS patients have high Natalizumab concentrations at time of re-dosing. multiple sclerosis (Houndmills","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00143-0"},{"key":"2026081401350938000_95.5.392.11","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"2026081401350938000_95.5.392.12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.13","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of Natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"key":"2026081401350938000_95.5.392.14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.msard.2019.05.017","article-title":"Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab","volume":"33","author":"Dekker","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2026081401350938000_95.5.392.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2026081401350938000_95.5.392.16","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512460604"},{"key":"2026081401350938000_95.5.392.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.157"},{"key":"2026081401350938000_95.5.392.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0058-z"},{"key":"2026081401350938000_95.5.392.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330467"},{"key":"2026081401350938000_95.5.392.20","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of Natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"key":"2026081401350938000_95.5.392.21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/13524585221130949","article-title":"Serum Neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from Every-4-week dosing in real-world clinical practice","volume":"29","author":"Foley","year":"2023","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.22","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1177\/13524585221108080","article-title":"No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab","volume":"28","author":"Johnsson","year":"2022","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312940"},{"key":"2026081401350938000_95.5.392.24","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614540224"},{"key":"2026081401350938000_95.5.392.25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2026081401350938000_95.5.392.26","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211042458","article-title":"No evidence for loss of natalizumab effectiveness with Every-6-week dosing: a propensity score-matched comparison with Every-4-week dosing in patients enrolled in the Tysabri observational program (TOP)","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026081401350938000_95.5.392.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323472"},{"key":"2026081401350938000_95.5.392.28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"2026081401350938000_95.5.392.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front Immunol"},{"key":"2026081401350938000_95.5.392.30","doi-asserted-by":"crossref","first-page":"117385","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J Neurol Sci"},{"key":"2026081401350938000_95.5.392.31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2026081401350938000_95.5.392.32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000904","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","volume":"8","author":"Toorop","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350938000_95.5.392.33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener Dis Manag"},{"key":"2026081401350938000_95.5.392.34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy060"},{"key":"2026081401350938000_95.5.392.35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1352458517728814","article-title":"Anti-JCV Serology during Natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham Polyoma virus Sero-conversion rates under Natalizumab treatment and differences between technical and biological Sero-Converters","volume":"24","author":"Schwab","year":"2018","journal-title":"Mult Scler"},{"key":"2026081401350938000_95.5.392.36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22074"},{"key":"2026081401350938000_95.5.392.37","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0530-8"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T09:37:43Z","timestamp":1786873063000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/jnnp-2023-332119"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332119","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}